Day: December 9, 2024

DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis

New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with daratumumab SC...

Prezent Sets New Milestones with Record Revenue in 2024, Unveils AI-Driven Vision for Enterprise Communication, and Secures Backing from New Investors True Global Ventures and Zoom Ventures to Accelerate Hyper-Growth in 2025

error: Content is protected !!